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Purpose: Macular Telangiectasia Type 2 (MacTel-2) is a retinal disease that can cause loss of 
central vision. To gain better understanding of the aetiology and pathogenesis of the MacTel-2, we 
investigated antigens which prompt the generation of retinal autoantibodies in the sera of MacTel-2 
patients. 
Methods: We screened for the presence of retinal autoantibodies in 45 sera collected from MacTel-
2 patients and 68 sera from healthy controls by Western Blot. We then isolated and identified three 
retinal proteins which are putative targets of three most frequently detected autoantibodies in the 
sera of MacTel-2 patients, using chromatographic fractionation and Liquid chromatography-tandem 
mass spectrometry (LC-MS/MS). We also validated the retinal location of the three antigens by 
immunohistochemisty using both MacTel-2 sera as primary antibodies, as well as commercial 
antibodies.  
Results: Retinal autoantibodies were detected in a significantly higher proportion of MacTel-2 
patients than in healthy controls (31/45 [69%] vs. 9/58 [16%], P<0.0001). The three antigens that 
were targeted by the most frequently detected MacTel-2 autoantibodies were identified as Glycogen 
debranching enzyme (AGL), Retinol-binding protein 3 (RBP3) and Creatine kinase type-B (CK-B). 
Autoantibodies against above antigens were found in 4, 11 and 9 MacTel-2 sera respectively.    
Conclusions: We found that most MacTel-2 patients possess retinal autoantibodies, the most 
prevalent of which were directed against AGL, RBP3 and CK-B. The localisation of retinal proteins 
bound by AGL, BRP3 and CK-B autoantibodies is consistent with their putative physiological 
functions. These findings provide potentially novel mechanisms for the aetiology and pathogenesis 
of MacTel-2.  
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Introduction 
The retina is thought to be an ‘immune-privileged’ site, which allows it to tolerate the introduction 
of antigens without eliciting an inflammatory immune response. This may protect the retina from 
inflammatory damage which would have potentially disastrous consequences for vision, since the 
retina has very limited regenerative capacity 1.   
The blood-retinal barrier (BRB) is the interface between systemic circulation and the retina. 
It consists of non-fenestrated capillaries of the retinal circulation with tight-junctions between 
retinal vascular endothelial and retinal pigment epithelial cells. The BRB’s ability to prevent free 
entry and exit of cells and larger molecules into and out of the retina is critical for the maintenance 
of immune-privilege.  Breakdown of the BRB is an important feature of many retinal diseases, 
including Macular Telangiectasia Type 2 (MacTel-2), Age-Related Macular Degeneration (AMD), 
and Diabetic Retinopathy (DR) 2-4.  Breakdown of the BRB exposes retinal antigens to the immune 
system, eliciting an inflammatory response which can cause tissue damage and vision loss5. 
Autoantibodies against retinal antigens have been detected from a number of ocular disorders 
including autoimmune retinopathy 6, 7 and AMD 8-10.  
MacTel-2 is a potentially blinding condition of the retina, yet its aetiology and pathological 
mechanisms remain poorly understood 4. Although it has been reported that MacTel-2 is present in 
0.1% of the population above 43 years of age, the actual prevalence may be higher 4, 11. MacTel-2 
affects both eyes with a predilection for the temporal parafovea 12. Leak is seen on fluorescein 
angiography but cystic oedema is usually absent. Biomicroscopic features of MacTel-2 include 
right angle vessels and deep retinal neovascularisation, loss of macular transparency, superficial 
white crystals, inner retinal cavitation without retinal thickening, foveal thinning and photoreceptor 
atrophy.  
In order to explore this retinal disease further, retinal autoantibodies were profiled in sera of 
MacTel-2 patients and the results were compared with that obtained from healthy controls. We first 
screened for the presence of autoantibodies in sera of MacTel-2 patients and then isolated the target 
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antigens through chromatography, which were subsequently subjected to Liquid chromatography–
tandem mass spectrometry (LC-MS/MS) for protein identification. We then performed 
immunohistochemical studies on human retinae using MacTel-2 sera as primary antibodies to 
identify the retinal cell types that were bound by the target autoantibodies. These results were 
further validated using commercially available antibodies.    
 
Material and methods 
Patient information and serum collection  
The study was approved by the Human Research Ethics Committee of the South Eastern Sydney 
Local Health District - Northern Sector, NSW, Australia. Written informed consent was obtained 
from all participants who donated serum. This research adhered to the tenets of the Declaration of 
Helsinki. 
Peripheral blood samples were collected from participants in The Natural History 
Observation Study of MacTel-2 (NHO MacTel-2) 13. The inclusion and exclusion criteria for 
enrolment in the NHO MacTel-2 were a clinical diagnosis of bilateral MacTel-2, who did not have 
DR or were afflicted with only background DR (less than ten microaneurysms without retinal 
haemorrhage) but without other confounding ocular conditions that may have prevented the 
evaluation of the condition (Table 1).  
The final diagnosis of MacTel-2 was confirmed by the Moorfields Reading Centre at 
Moorfields Eye Hospital, London, UK on the basis of colour fundus photographs, optical coherence 
tomography (OCT) scans, fundus fluorescein angiography, fundus autofluorescence, blue light 
reflectance and microperimetry. The diagnosis was confirmed in all cases by attenuation of central 
masking of background autofluorescence by luteal pigment with other signs, including temporal 
parafoveal telangiectasis with late staining seen on fluorescein angiography, superficial white 
crystals, foveal thinning, inner retinal cavitation and photoreceptor disruption seen on OCT. 
Breakdown of the blood-retinal barrier was graded by an experienced retinal clinician (MG) on the 
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extent of leakage during angiography 5 minute after fluorescein injection as absent, mild, moderate 
or severe 
For healthy controls, blood samples were collected from a group of people who were 
enrolled into the NHO MacTel-2 study as blood relatives or non-blood related controls of MacTel-2 
patients. The Moorfields Reading Centre confirmed that they had neither MacTel-2 nor other retinal 
diseases based on their clinical signs and the ocular images.  
Retina tissue processing  
Five post-mortem human (age from 62-75) retinae were obtained from the Lions NSW Eye Bank, 
Sydney, Australia following the Australian Therapeutic Goods Administration (TGA) guidelines for 
the use of human tissues for research. The ethics approval for the use of post-mortem human tissues 
for this project was obtained from the University of Sydney Ethics Committee, Sydney, Australia.  
Human retinae were homogenized in RIPA buffer with protease inhibitor complex (Roche, 
Australia). The homogenates were constantly shaken for 30 minutes (4° C, 60 rpm) then centrifuged 
at 12000g for 30 minutes at 4° C. Supernatants were collected, pooled and stored at -80° C until use. 
Protein concentration was determined using BCA protein assay (Sigma, Australia). Total retinal 
protein homogenates were mixed with NuPAGE loading dye (4x) and reducing buffer (10x) 
(Invitrogen, Australia), then heated for 10 minutes at 70° C. The supernatant was collected after 
centrifugation at 12000g for 5 minutes.  
Autoantibody screening 
Approximately 1 µg of protein was loaded per 1mm of the NuPAGE Tris-Bis gel (Invitrogen, 
Australia). The precast gels were manually modified to include a single small well for loading the 
protein standard and a large “prep” well (~ 6.5 mm length) allowing the total retinal protein sample 
to be applied across the whole gel. Proteins were separated by electrophoresis at constant 180V at 4° 
C for 1 hour.  The gels were transferred onto PVDF membrane (Millipore, Australia) at constant 
100V at 4 ° C for 1 hour.  
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The PVDF membranes were incubated in 5% BSA, 0.1% tween, TBST for 1 hour at room 
temperature to block non-specific binding. Serum from each participant was diluted (1:200) and 
reacted with the membrane overnight at room temperature. A multiscreen apparatus (Bio-Rad, 
Australia) allowed the large area of blotted protein to be divided into individual chambers, therefore 
a single blot could be used to test sera from up to 18 individuals. Each chamber had a total volume 
of 600 µL. 
After overnight incubation in sera, membranes were washed in 0.1% TBST three times then 
incubated with goat anti-human IgGAM (1:10000, Invitrogen, Australia) at room temperature for 1h. 
This polyclonal antibody recognizes both heavy and light chains of human IgG, IgA and IgM. After 
three washes in 0.1% TBST, the blot was incubated in ECL Western Blotting (WB) detection 
reagent (Millipore, Australia) for 5 minutes and photographed using the G-Box imaging system (In 
Vitro Technologies, Australia).  
Chromatography Fraction 
Total human retinal protein was extracted by RIPA buffer as described above. The dialysis was 
performed in Buffer A (50 mM Tris Ph 8.0), and then loaded into an iron exchange column (HiTrap 
Q HP, 1 ml, GE Healthcare, Australia). Proteins were eluted out based on their different surface 
charges. Different elution fractions of 0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% and 
100% of Buffer B (1M NaCl, 50 mM Tris Buffer Ph 8.0) were collected and subjected to WB for 
tracking the antigen, in which sera from MacTel-2 patients were used as primary antibodies.   
The antigen-containing fraction was further dialyzed into 1M Ammonium sulfate and 50 
mM potassium phosphate buffer Ph 7.5, then loaded onto a Hydrophobic Interaction 
Chromatography Column (HiTrap Butyl HP, GE healthcare, Australia). Proteins were eluted out 
based on their different hydrophobicity. Different elution fractions were collected and subject to 
WB to track the antigens as described above.   
The antigen-containing fractions were dialyzed to exclude the salt and then concentrated. 
Fractions were run in parallel on two identical 4-12% NuPAGE Tris-Bis gels (Invitrogen, Australia) 
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at a constant 180W for 1 hour. The first gel was processed for WB using MacTel-2 sera to identify 
the exact position of the target antigen. Protein bands were stained in the second gel with 
SimplyBlue SafeStain (Invitrogen, Australia).  The desired antigen-containing bands in the second 
gel were identified using the corresponding migration distance of the target proteins in the 
membrane subjected to WB.  The antigen-containing bands in the second gel were excised, 
destained and dried before being digested overnight using trypsin (Promega, Australia). Digests 
were extracted using 60% acetonitrile (ACN)/ 0.1% trifluoroacetic acid. The extracts were dried 
with a speed vacuum and reconstituted in 5% ACN/0.1% formic acid and applied to reverse phase 
NanoLC mass spectrometry (Australian Proteome Analysis Facility, APAF). 
Tandem mass spectrometry data acquisition 
The digests were dissolved in 40 μL of ESI loading buffer, injected onto a peptide trap (Michrome 
peptide Captrap) for pre-concentration and desalted with 0.1% formic acid, 2% ACN, at 8μL/min. 
The peptide trap was switched in line with the analytical column. Peptides were eluted from the 
column, using a linear solvent gradient, stepwise from H2O:CH3CN (100:0, + 0.1% formic acid) to 
H2O:CH3CN (10:90, + 0.1% formic acid) at 500nL/min over 80 min. The LC eluent was analysed 
with positive ion nanoflow electrospray MS on QSTAR, which was operated in an information 
dependant acquisition mode (IDA). In IDA mode, a TOF MS survey scan was acquired (m/z 400-
1600, 0.5s) with the three largest multiply charged ions (counts >25) sequentially subjected to 
tandem mass spectrometry analysis. MS/MS spectra were accumulated for 2 s (m/z 100-1600). 
Data processing 
The data were exported and submitted to the database search program, ascot (Matrix Science Ltd, 
London UK). Peaklists were searched against Homo sapiens in SwissProt database. High scores in 
the database search indicate a likely match which is confirmed or qualified by operator inspection. 
Immunohistochemistry (IHC) 
Two post-mortem human eyes from healthy donors were used for immunohistochemical studies.  
The approximate time from death of the patient to storage of the globe was 12 hours. After 
8 
 
removing corneas, eye cups were fixed in 4% paraformaldehyde for 4 hour followed by 
equilibration in 20% sucrose overnight. After dissecting eye cups into smaller pieces, tissues were 
embedded in Optical Cutting Temperature Compound (ProSciTech, Australia) for cyrosectioning. 
In order to identify the types of retinal cells targeted by autoantibodies detected in MacTel-2, 
cyrosections (10µm) were incubated with 1: 50 dilutions of MacTel-2 sera, overnight at 4°C. 
Antibody binding was detected by incubation of sections with goat anti-human IgG (H+L) 
conjugated with Alexa Fluor 488 (1:1000, Invitrogen) at 37°C for 2 hours. The nuclei were 
counterstained with 10 μg/ml propidium iodide in PBS for 5 min. The stained sections were 
examined with a confocal microscope (LSM700, Carl Zeiss). 
To validate the results of IHC in which MacTel-2 sera were used as primary antibodies, 
cyrosections were also incubated with commercial antibodies against proteins revealed by Tandem 
Mass Spectrometry data acquisition. The commercial antibodies used for further validation included 
anti-creatine kinase B type (CK-B, Santa Cruz, #sc-1517); anti-retinol-binding protein 3 
(RBP3,Abcam, #ab101456) and anti-glycogen debranching enzyme (AGL, C-term, Abgent, 
AP2402b).  IHC was performed as described above.  
Results 
Retinal autoantibody detection 
Forty-five blood samples were collected from confirmed MacTel-2 patients and 68 samples from 
healthy controls. To detect autoantibodies present in MacTel-2 sera, we performed WB analysis 
using sera as primary antibodies to probe the total proteins extracted from human retinae. Various 
band patterns were detected, especially in membranes blotted with MacTel-2 sera (Figure 1A). 
Overall, we detected autoantibodies against human retinal proteins in 68% (31/45) of MacTel-2 sera, 
while only 16% (9/58) of healthy controls showed positive bands (Table 1, P<0.0001). Fisher’s 
exact test gave an odds ratio of 12.1, indicating that the likelihood of MacTel-2 patients having 
retinal autoantibodies is significantly greater than individuals in the healthy control group. 
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         Three bands were frequently detected in MacTel-2 sera, which did not appear in sera from 
healthy controls. We named these three unknown proteins antigen X (~150 kDa), antigen Y (~120 
kDa) and antigen Z (~40 kDa) (Figure 1B). Autoantibodies against antigens X, Y and Z were found 
in 4, 11 and 9 MacTel-2 sera respectively. In addition, we also detected low MW (less than 40 kDa) 
autoantibody band in 7 MacTel-2 sera, but were not detected in multiple patients.  Not surprisingly, 
we also detected 16% (9/58) of healthy control sera containing low MW autoantibody bands when 
probing against human total retinal proteins. No samples shared a MW similar to X, Y or Z. This is 
consistent with a report identifying a certain percentage [19% (15/79)] of low MW autoantibodies 
detected in healthy control sera 14.  
Reviewing the clinical data of all these Mactel-2 patients with autoantibody X, Y or Z 
revealed that most patients were afflicted with advanced MacTel-2. Two of 11 patients with 
autoantibody Y were observed to have retinal hyper autofluorescence, which occurs in only around 
5% of the general population with MacTel 15. Patients in autoantibody Z groups exhibited more 
pronounced BRB breakdown than other cases (data not shown). 
Antigen fractionation and identification 
To identify the three retinal proteins targeted by the three autoantibodies which were detected in the 
MacTel-2 sera, chromatography was used to fractionate the human retinal proteins.  As described in 
the methods, we first separated human retinal protein lysates by the surface charge using an ion 
exchange column (Q column) and then chose the fractions containing our target antigens to be 
further isolated by hydrophobicity using a hydrophobic column (Butyl column). Each isolation step 
was validated by WB using MacTel-2 sera containing the autoantibody against antigen X, Y or Z. 
(Figure 2A-C, indicated by asterisks). The antigen-containing protein fraction was then run, in 
parallel, on two identical SDS-PAGE. The first gel was used to identify the exact position of the 
target antigen by WB using MacTel-2 serum containing target autoantibody. The desired antigen-
containing band stained by SimplyBlue in the second gel was identified using the corresponding 
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migration distance of the target protein in the membrane subjected to WB. The antigen-containing 
band in the second gel was excised (Figure 2D-F, asterisks), purified and analysed with LC-MS/MS.  
As shown in Table 2, the LC-MS/MS analysis revealed antigen X as Glycogen Debranching 
Enzyme (AGL), a protein related to energy metabolism 16, antigen Y as Retinol-Binding Protein 3 
(RBP3), which is known to play important roles in the visual light cycle 17 and antigen Z as 
Creatine kinase Brain type (CK-B), which is a factor involved in energy metabolism in the visual 
cycle 18. LC-MS/MS analysis detected multiple matching sequences consistent with our predicted 
target proteins, which confirmed our earlier analysis. See Supplementary material for details of LC-
MS/MS results for three antigens identification.  
Antigen localisation 
IHC was conducted using MacTel-2 sera and commercial antibodies against AGL, RBP3 and CK-B 
to localize the target cell types in human retinae.  (Figures 3 and 4, Table 3).   IHC using MacTel-2 
serum containing anti-AGL as a primary antibody produced strong immunostaining around retinal 
blood vessels in the inner retina, along with weak staining in astrocytes and cells in both the inner 
nuclear layer (INL) and outer nuclear layer (ONL) (Figure 3A-C). IHC using a commercial anti-
AGL antibody produced a similar immunoreactivity pattern (Figure 4A-C). IHC with MacTel-2 
serum containing anti-RBP3 showed that RBP3, a molecule responsible for the transfer of 11-cis 
retinal and all trans-retinol between the photoreceptors and retinal pigment epithelium (RPE) 19, was 
abundantly expressed in the photoreceptor outer segments (Figure 3D-F).  This finding was further 
confirmed by immunostaining using a commercial anti-RBP3 antibody (Figure 4D-F). IHC with 
MacTel-2 serum containing anti-CK-B showed that CK-B was globally expressed throughout the 
entire retina and high CK-B expression was observed in the photoreceptor outer segments (Figure 
3G-I). Immunostaining using a commercial anti-CK-B antibody revealed similar staining results to 
those observed with CK-B serum (Figure 4G-I). To further confirm the identity of the Z antigen as 
CK-B, we blotted patient serum against a recombinant CK-B protein.   Sera from all All nine 
patients were positive for recombinant CK-B protein when compared with health control serum 
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(Supplementary Figure 1). There was no obvious immunoreactivity in the human retina when 
healthy control sera was used as primary antibodies for IHC (Figure 3J-L). Thus these IHC results 
indicate that MacTel-2 patients can produce autoantibodies to target specific retinal proteins.  
 
Discussion 
This study is the first to report the presence of autoantibodies against retinal proteins in sera from 
people with MacTel-2. We identified three retinal proteins, including AGL, RBP3 and CK-B, which 
appear to be the targets for many of these autoantibodies. These data may serve as a foundation for 
further studies aimed at elucidating the pathogenic mechanisms that cause MacTel-2. 
AGL is involved in glycogen metabolism through facilitating glycogen breakdown20.  
Immunohistochemistry revealed AGL was found mainly around inner retinal vessels, with weak 
expression in astrocytes and cells of both the INL and ONL. It has been reported that glycogen may 
be used by Muller cells to generate lactate for neighbouring cells 21, 22. Our previous proteomics 
study determined there is a downregulation of glycolytic pathway proteins in the retina of a patient 
afflicted with MacTel-2 23. The glycolytic pathway is dominant in glial cells, including astrocytes in 
the superficial retina and Muller cells which span the full thickness of the neural retina. 
Compromise of this pathway may affect the energy supply of photoreceptors. This might be 
exacerbated by the presence of AGL autoantibodies in MacTel-2 patients. Autoantibodies against 
AGL have not been reported for any other retinal disease. Whether anti-AGL autoantibody could be 
used as a biomarker, unique to MacTel-2, warrants further investigation. 
RBP3 is essential for the exchange of retinoid between the RPE and photoreceptors. The 
presence of sufficient quantities of functional RBP3 is also critical to photoreceptor survival since it 
serves to prevent the potentially cytotoxic effects of retinoids. We detected RBP3 autoantibody in 
around 25% (11/45) of MacTel-2 patients and our IHC studies found these autoantibodies bound 
photoreceptor outer segments strongly. Intriguingly, also found RBP3 autoantibody in 33.3% (6 out 
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of 18) of AMD patients’ sera (unpublished data). Detection of a common autoantibody might 
indicate that both MacTel-2 and AMD share some common aetiologic or pathogenic mechanisms.   
It is possible that RBP3 autoantibodies could contribute to outer retinal degeneration.  
Reduced levels of functional RBP3 protein in the interphotoreceptor matrix might interfere with the 
visual cycle that represents the natural exchange of proteins between the photoreceptors and RPE. 
This disruption could result in the accumulation of all-trans retinol, which is readily transformed 
through condensation to N-retinylidene-N-retinylethanolamine (A2E) 24, a prominent component of 
the retinal ‘waste product’ lipofuscin. A2E is also known to be responsible for retinal 
autofluorescence, a phenomenon that is a standard AMD diagnostic marker 25, 26. Increased 
autofluorescence due to accumulation of subretinal debris has also been observed in a small 
proportion MacTel-2 patients 15, 27. 
CK-B is an important enzyme for vertebrate energy metabolism 18. It catalyses the 
conversion of creatine, consuming adenosine triphosphate (ATP), phosphocreatine and adenosine 
diphosphate (ADP), in the visual cycle 18. CK-B is critical for providing energy for the visual cycle 
in photoreceptors. CK-B autoantibody has been detected in 25% of people with Vogt-Koyanagi-
Harada disease and 38% of those with sarcoidosis 28, prevalences which are similar to the 20% 
(9/45) that we found in people with MacTel-2.  Interestingly, sera from patients with DR, 
paraneoplastic sensory-dominant neuropathy and non-paraneoplastic autoimmune retinopathy has 
also been reported to contain autoantibodies binding to CK-B 29-31. We found CK-B antibodies 
globally expressed throughout the retina, with a particularly high expression in photoreceptor outer 
segments. Since CK-B is abundantly expressed in the retina 18, the presence of CK-B antibody in 
MacTel-2 patients may adversely affect their visual function. After reviewing the clinical data of all 
9 patients whose sera contained CK-B antibody, we found all these patients exhibitedmore 
pronounced BRB breakdown, determined angiographically, than individuals from the set of people 
with MacTel-2.  This suggests that the presence of CK-B autoantibody in these patients may 
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contribute to retinal vasculopathy and may have clinical significance for the early diagnosis of 
retinal vascular diseases such as MacTel-2 and DR. 
A potential mechanism underlying the generation of retinal autoantibodies is the activation 
of microglia by the stressed retina. Activated microglia may phagocytose target retinal antigens and 
then enter the systemic circulation where they may become antigen presenting cells32.  This could 
result in a vicious circle, whereby more autoantibodies pass the compromised BRB leading to an 
increase of phargocytosed antigens.  This would not only impair the function of these antigens, but 
also damage surrounding areas due to inflammation.  
MacTel-2 remains poorly understood, both aetiologically and pathologically. The presence 
of different autoantibodies in people with MacTel-2 suggests that the clinical picture might be 
produced by different pathogenic processes.  For instance, autoantibodies against AGL may 
contribute to impairment of the glycolytic pathway. RBP3 autoantibodies might contribute to 
photoreceptor damage since most of MacTel-2 patients with this autoantibody were at a more 
advanced pathogenic stage.  CK-B autoantibody was detected in MacTel-2 patients with more 
pronounced vasculopathy. Clinically there is great variation in the degree of neuronal or vascular 
damage from one patient to another. Further studies on the relationship between different 
autoantibodies,clinical phenotypes and progression rates are warranted.  
In summary, we found that most MacTel-2 patients possess retinal autoantibodies, the most 
prevalent of which were directed against AGL, RBP3 and CK-B. The localization of retinal proteins 
bound by AGL, BRP3 and CK-B autoantibodies was consistent with their putative physiological 
functions.  These findings provide potentially novel mechanisms for the aetiology and pathogenesis 
of MacTel-2. Further studies will be required to determine whether these autoantibodies have a 
causative role in photoreceptor damage and BRB breakdown or whether they are simply a 
secondary phenomenon which is a non-specific reaction to retinal disease.   
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Table 1. Patient information and autoantibodies present ratio. 
 
Table 2. Detail information of MS/MS identified target antigens. 
 
Table 3. Immunohistochemistry in human retinas using MacTel-2 sera as primary antibodies 
and confirmation of the results using commercial antibodies. 
 
Figure Legends 
Figure 1. Retinal autoantibody detection by Western Blot. A. Total human retinal protein blotted 
with individual MacTel-2 patient’s serum or control human serum. Bands indicate different retinal 
autoantibodies in MacTel-2 sera. B. Three different sizes of bands were detected by Western Blot. 
Antigen X (~150 kDa), Antigen Y (~120 kDa) and Antigen Z (~40 kDa) were frequently observed 
in MacTel-2 sera (asterisks) but not present in healthy controls.  
Figure 2. Fractionation and separation of target antigen. A-C. Chromatographic separation of 
antigen X, Y and Z from total human retinal proteins identified by autoantibody detection through 
 
Number of 
participants 
Mean age
(years) 
Age range
(years) 
Sex 
(M/F)
Diabetes/ 
Non 
Diabetes 
Autoantibodies 
present, n (%) 
 
Control 58 45 21-78 28/30 13/45 9 (15.5%) 
Mactel 45 59 37-79 18/27 11/34 31(68.9 %) 
Target Peptide Protein Name OS Mass Protein Score Matches sequences emPAI 
X Glycogen debranching enzyme Homo spiens 174652 301 17(8) 17(8) 0.28 
Y Retinol-binding protein 3 Homo spiens 135278 2746 83(61) 45(43) 2.84 
Z Creatine kinase B-type Homo spiens 42617 8314 164(153) 27(27) 25.72 
Protein Name Cellular Localization in the Human Retina Function 
AGL 
strong staining around inner retinal vessels, 
weak staining in astrocytes and cells in the 
inner nuclear layer and outer nuclear layer 
Glycogen metabolism, facilitating glycogen breakdown
RBP3 Photoreceptor outer segments 
Visual cycle trafficking, responsible for transfer of 11-
cis retinal and all trans retinol between photoreceptors 
and retinal pigment epithelium 
CK-B 
Globally expressed throughout the entire retina 
and high expression was observed in the 
photoreceptor outer segments 
Energy metabolism, providing energy for the visual 
cycle 
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Western blot. Asterisks indicate fractions containing target antigens. D-F. SDS PAGE further 
separated the target antigens. Asterisks indicate the target bands cut out for MS. 
Figure 3. Immunohistochemistry in human retinae using MacTel-2 sera containing different 
autoantibodies identified by chromatographic fractionation and tandem mass spectrometry.  
Healthy subject serum was used as a control. Sections were also stained with propidium iodide (PI) 
for nuclear counterstaining. . A-C. MacTel-2 serum containing anti-AGL autoantibody. D-F. 
MacTel-2 serum containing anti-RBP3 autoantibody. G-I. MacTel-2 serum containing anti- CK-B 
autoantibody. J-L.  Healthy subject serum without autoantibody. GCL: Ganglion cell layer, INL: 
inner nuclear layer, ONL: out nuclear layer. Scale bars: 60µm. 
Figure 4. Immunohistochemistry using commercial antibodies against AGL (A-C), RBP3 (D-F) 
and CK-B (G-I). Sections were also stained with propidium iodide (PI) for nuclear counterstaining. 
GCL: Ganglion cell layer, INL: inner nuclear layer, ONL: out nuclear layer. Scale bars: 60µm.  
Supplementary material 
Supplementary Figure 1. 
Recombinant human Creatine Kinase B-type protein (Abcam, ab73647) blotted with individual 
MacTel-2 patient’s serum with putative CK-B autoantibody (Z) or control healthy human serum (C). 
Bands indicate CK-B autoantibody in serum. 
Details of LC-MS/MS results for three antigens identification. 
AGL_Mascot.pdf 
RBP3_Mascot.pdf 
CKB_Mascot.pdf 
 




